CCM logo

Concord Medical Services Holdings Limited (CCM) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $4.80, Concord Medical Services Holdings Limited (CCM) es una empresa del sector Healthcare valorada en 698947. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 15 mar 2026
Puntuación de IA de 43/100 MCap 699K Vol 48K

Concord Medical Services Holdings Limited (CCM) Resumen de Asistencia Médica y Tuberías

CEOJianyu Yang
Empleados595
Sede CentralBeijing, CN
Año de la oferta pública inicial (OPI)2009

Concord Medical Services Holdings Limited, based in China, operates a network of radiotherapy and diagnostic imaging centers. The company offers a comprehensive suite of cancer treatment and diagnostic services, including radiotherapy, gamma knife radiosurgery, and diagnostic imaging. It also provides clinical support and equipment leasing, positioning it as an integrated oncology solutions provider.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 15 mar 2026

Tesis de Inversión

Concord Medical Services Holdings Limited presents a complex investment case. The company's negative profit and gross margins (-44.6% and -11.4% respectively) indicate significant challenges in achieving profitability. The company's beta of -1.23 suggests an inverse correlation to the market, which may appeal to investors seeking diversification. Growth catalysts include expanding its network of cooperative centers and hospitals, and increasing adoption of advanced radiotherapy techniques. However, investors should closely monitor the company's ability to improve its financial performance and navigate the regulatory landscape in China's healthcare sector.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Operates a network of 16 cooperative centers based in 13 hospitals as of December 31, 2021.
  • Offers a range of radiotherapy services, including linear accelerator external beam radiotherapy and gamma knife radiosurgery.
  • Provides diagnostic imaging services, including computed tomography (CT) scans.
  • Offers clinical support services, such as developing treatment protocols and organizing joint diagnoses.
  • Operates specialty cancer hospitals providing radiotherapy, diagnostic imaging, chemotherapy, and surgery.

Competidores y Pares

Fortalezas

  • Established network of radiotherapy and diagnostic imaging centers in China.
  • Comprehensive suite of cancer treatment services.
  • Expertise in advanced radiotherapy techniques.
  • Strong relationships with hospitals and medical professionals.

Debilidades

  • Negative profit margin and gross margin.
  • Reliance on cooperative centers within hospitals.
  • Exposure to regulatory risks in China's healthcare sector.
  • Limited geographic diversification.

Catalizadores

  • Ongoing: Expansion of the network of cooperative centers and specialty cancer hospitals.
  • Ongoing: Increasing adoption of advanced radiotherapy techniques, such as IMRT and SBRT.
  • Ongoing: Strategic partnerships with other healthcare providers and technology companies.

Riesgos

  • Ongoing: Negative profit margin and gross margin, indicating financial challenges.
  • Potential: Changes in government regulations and healthcare policies in China.
  • Potential: Competition from other radiotherapy and diagnostic imaging providers.
  • Potential: Technological advancements that could render existing equipment obsolete.

Oportunidades de crecimiento

  • Expansion of Cooperative Centers: Concord Medical has the opportunity to expand its network of cooperative centers within existing and new hospitals across China. This expansion can increase its geographic reach and patient access, driving revenue growth. The market for radiotherapy services in China is projected to grow, driven by increasing cancer incidence and government support for advanced medical technologies. A realistic timeline for adding 2-3 centers per year over the next 3-5 years could significantly boost revenue.
  • Adoption of Advanced Radiotherapy Techniques: The company can drive growth by promoting the adoption of advanced radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT). These techniques offer more precise and effective cancer treatment, attracting patients seeking advanced care. The market for advanced radiotherapy is growing rapidly, with increasing demand from both patients and physicians. Concord Medical can invest in training and technology to become a leader in this area.
  • Development of Specialty Cancer Hospitals: Concord Medical can further develop its specialty cancer hospitals, offering a full range of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. This integrated approach can attract patients seeking comprehensive cancer care under one roof. The market for specialty cancer hospitals is growing, driven by increasing demand for specialized cancer treatment services. The company can invest in expanding its hospital network and enhancing its service offerings.
  • Strategic Partnerships: Concord Medical can pursue strategic partnerships with other healthcare providers, research institutions, and technology companies to expand its service offerings and market reach. These partnerships can provide access to new technologies, expertise, and patient networks. The healthcare industry is increasingly collaborative, with companies forming partnerships to leverage each other's strengths. Concord Medical can explore partnerships with companies specializing in areas such as genomics, immunotherapy, and artificial intelligence.
  • Teleconsultation and Medical IT Services: The company can leverage teleconsultation and medical IT services to improve patient access and streamline operations. Teleconsultation can enable remote consultations with specialists, while medical IT services can improve data management and treatment planning. The market for telemedicine and medical IT is growing rapidly, driven by increasing adoption of digital health technologies. Concord Medical can invest in developing its teleconsultation platform and medical IT infrastructure.

Oportunidades

  • Expansion of cooperative centers and specialty cancer hospitals.
  • Adoption of advanced radiotherapy techniques.
  • Strategic partnerships with other healthcare providers.
  • Growth in China's healthcare market.

Amenazas

  • Competition from other radiotherapy and diagnostic imaging providers.
  • Changes in government regulations and healthcare policies.
  • Technological advancements that could render existing equipment obsolete.
  • Economic downturn in China.

Ventajas competitivas

  • Established network of cooperative centers and hospitals across China.
  • Comprehensive suite of cancer treatment and diagnostic services.
  • Expertise in radiotherapy and diagnostic imaging.
  • Strong relationships with hospitals and medical professionals.

Acerca de CCM

Founded in 1997 and headquartered in Beijing, Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers across the People's Republic of China. The company has evolved into a comprehensive provider of cancer treatment solutions, operating through two primary segments: Network and Hospital. The Network segment focuses on providing radiotherapy and diagnostic imaging services through cooperative centers located within hospitals. These services include linear accelerator-based external beam radiotherapy, gamma knife radiosurgery, and diagnostic imaging using computed tomography scanners. Concord Medical also offers clinical support services, such as developing treatment protocols, organizing joint diagnoses, and assisting with the recruitment and compensation of medical personnel. The Hospital segment involves the operation of specialty cancer hospitals, offering a full spectrum of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. As of December 31, 2021, Concord Medical operated 16 cooperative centers in 13 hospitals. In addition to its core services, the company engages in radiotherapy and diagnostic equipment leasing, management services, premium cancer and proton treatment services, teleconsultation, and medical information technology services. It also sells medical equipment.

Qué hacen

  • Operates a network of radiotherapy and diagnostic imaging centers in China.
  • Provides linear accelerator external beam radiotherapy.
  • Offers gamma knife radiosurgery for head and body tumors.
  • Performs diagnostic imaging services using CT scanners.
  • Provides clinical support services to doctors.
  • Offers radiotherapy and diagnostic equipment leasing.
  • Operates specialty cancer hospitals offering comprehensive cancer treatments.

Modelo de Negocio

  • Generates revenue from radiotherapy and diagnostic imaging services provided through its network of cooperative centers.
  • Earns revenue from the operation of specialty cancer hospitals, offering a range of cancer treatments.
  • Derives income from leasing radiotherapy and diagnostic equipment to hospitals.
  • Receives fees for providing management services to hospitals.
  • Generates revenue from the sale of medical equipment.

Contexto de la Industria

Concord Medical Services Holdings Limited operates within China's growing healthcare market, specifically in the oncology sector. The demand for cancer treatment services is increasing due to an aging population and rising cancer rates. The competitive landscape includes both domestic and international players offering similar radiotherapy and diagnostic imaging services. Concord Medical differentiates itself through its network of cooperative centers and hospitals, providing a comprehensive suite of cancer treatment solutions. The industry is subject to regulatory oversight and technological advancements, requiring companies to adapt to changing market dynamics.

Clientes Clave

  • Patients seeking radiotherapy and diagnostic imaging services.
  • Hospitals that partner with Concord Medical to establish cooperative centers.
  • Hospitals that lease radiotherapy and diagnostic equipment from Concord Medical.
  • Patients seeking comprehensive cancer treatment at Concord Medical's specialty cancer hospitals.
Confianza de la IA: 70% Actualizado: 15 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Concord Medical Services Holdings Limited (CCM): $4.80 (+0.53, +12.41%)

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CCM.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CCM.

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CCM en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Jianyu Yang

CEO

Jianyu Yang is the Chief Executive Officer of Concord Medical Services Holdings Limited. Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational management of the company.

Historial: Under Jianyu Yang's leadership, Concord Medical Services Holdings Limited has continued to operate a network of radiotherapy and diagnostic imaging centers in China. Specific milestones and achievements under his tenure are not detailed in the provided data.

Información de ADR de Concord Medical Services Holdings Limited

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock, allowing it to trade on U.S. stock exchanges. For Concord Medical (CCM), each ADR represents a certain number of ordinary shares of the company traded on its home market. This allows US investors to invest in Concord Medical more easily.

  • Ticker del mercado local: Not specified in provided data. Primary stock exchange and country is required.
Riesgo cambiario: As an ADR, CCM is subject to currency risk. The value of the ADR is affected by fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan (CNY). If the CNY depreciates against the USD, the value of the ADR in USD terms may decrease, impacting returns for U.S. investors.
Implicaciones fiscales: The foreign dividend withholding tax rate for Chinese companies can vary, but is typically around 10%. A tax treaty between the U.S. and China may reduce this rate for eligible U.S. investors. Investors should consult a tax advisor to determine their specific tax obligations.
Horario de negociación: Trading hours for CCM's home market (China) and the U.S. market differ significantly. Chinese stock exchanges typically operate during local daytime hours, while U.S. exchanges operate during U.S. daytime hours. This difference in trading hours can impact the ability of U.S. investors to react to news and events in the Chinese market in real-time.

Lo Que los Inversores Preguntan Sobre Concord Medical Services Holdings Limited (CCM)

¿Cuáles son los factores clave para evaluar CCM?

Concord Medical Services Holdings Limited (CCM) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Established network of radiotherapy and diagnostic imaging centers in China.. Riesgo principal a monitorear: Ongoing: Negative profit margin and gross margin, indicating financial challenges.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CCM?

CCM actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CCM?

Los precios de CCM se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CCM?

La cobertura de analistas para CCM incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CCM?

Las categorías de riesgo para CCM incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit margin and gross margin, indicating financial challenges.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CCM?

La relación P/E para CCM compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CCM sobrevalorada o infravalorada?

Determinar si Concord Medical Services Holdings Limited (CCM) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CCM?

Concord Medical Services Holdings Limited (CCM) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data is limited to the provided information.
  • Analyst consensus is not available.
  • CEO background information is limited.
Fuentes de datos

Popular Stocks